Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19974287 | 0.82 | MTNR1A (0.42) | MTNR1AMTNR1BRIPK1RIPK3MAPT | |
| SCHEMBL17999509 | 0.81 | MTNR1A (0.42) | HCAR2MTNR1AMTNR1BCYP11B1CYP11B2 | |
| SCHEMBL3372685 | 0.80 | HCAR2 (0.46) | HCAR2SHMT1MAPTKMT2A | |
| SCHEMBL8983807 | 0.79 | MAOB (0.48) | HCAR2MAPTKMT2A | |
| SCHEMBL12302707 | 0.77 | MTNR1A (0.37) | MTNR1AMTNR1BRIPK1RIPK3 | |
| SCHEMBL19806204 | 0.76 | TSHR (0.43) | HCAR2CYP11B1CYP11B2MAPTKMT2A | |
| SCHEMBL1724531 | 0.76 | MTNR1A (0.36) | MTNR1AMTNR1BRIPK1RIPK3 | |
| SCHEMBL22068726 | 0.76 | KDM4E (0.48) | MAPTKMT2A | |
| SCHEMBL23169558 | 0.76 | STK17B (0.40) | MTNR1AMTNR1BRIPK1RIPK3MAPT | |
| SCHEMBL2427540 | 0.75 | MAPT (0.56) | MTNR1AMTNR1BMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402875-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2022-12-22 | — | — | US | disclosed |
| US-11472772-B2 | S1P3 antagonists | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2022-10-18 | — | — | US | disclosed |
| EP-3258929-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3896068-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2021-10-20 | — | — | EP | disclosed |
| EP-3689864-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2020-08-05 | — | — | EP | disclosed |
| US-20200157052-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2020-05-21 | — | — | US | disclosed |
| EP-3086845-B1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2019-11-20 | — | — | EP | disclosed |
| US-10351558-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180201582-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-07-19 | — | — | US | disclosed |
| US-9951017-B2 | S1P3 antagonists | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-04-24 | — | — | US | disclosed |
| EP-3258929-A1 | FACTOR IXa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-3086845-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2016-11-02 | — | — | EP | disclosed |
| US-20160297762-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2016-10-13 | — | — | US | disclosed |
| WO-2016133793-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2015082357-A1 | S1P3 ANTAGONISTS | SIENA BIOTECH S.P.A. (IT) | 2015-06-11 | — | — | WO | disclosed |
| EP-2878339-A1 | SIP3 antagonists | Siena Biotech S.p.A. (IT) | 2015-06-03 | — | — | EP | disclosed |
| EP-1745037-B1 | Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases | NOVARTIS AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| EP-2270001-A1 | Indolylmaleimide derivatives as PKC inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-7648989-B2 | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG (CH) | 2010-01-19 | — | — | US | disclosed |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201582-A1 | S1P3 ANTAGONISTS | S1PR3, S1PR5, S1PR1 | HCAR2 148/4885MTNR1A 302/4885MTNR1B 323/4885 |
| US-20160297762-A1 | S1P3 ANTAGONISTS | S1PR3, S1PR5, S1PR1 | HCAR2 148/4885MTNR1A 302/4885MTNR1B 323/4885 |
| US-20220402875-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | HCAR2 148/4885MTNR1A 302/4885MTNR1B 323/4885 |
| US-20200157052-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | HCAR2 148/4885MTNR1A 302/4885MTNR1B 323/4885 |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | PRKCE, PRKCH, PRKCI | HCAR2 3292/4885MTNR1A 3055/4885MTNR1B 2353/4885 |
| US-10351558-B2 | Factor IXa inhibitors | F9, TFPI, F12 | HCAR2 2776/4885MTNR1A 2916/4885MTNR1B 2253/4885 |
| US-11472772-B2 | S1P3 antagonists | S1PR3, S1PR5, S1PR1 | HCAR2 148/4885MTNR1A 302/4885MTNR1B 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.